1. Home
  2. OLMA vs EVO Comparison

OLMA vs EVO Comparison

Compare OLMA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olema Pharmaceuticals Inc.

OLMA

Olema Pharmaceuticals Inc.

HOLD

Current Price

$9.84

Market Cap

949.3M

Sector

Health Care

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.58

Market Cap

778.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLMA
EVO
Founded
2006
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
949.3M
778.3M
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
OLMA
EVO
Price
$9.84
$1.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
1
Target Price
$44.89
$7.00
AVG Volume (30 Days)
817.3K
41.4K
Earning Date
05-08-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
15.00
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
N/A
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.65
$1.60
52 Week High
$36.26
$4.27

Technical Indicators

Market Signals
Indicator
OLMA
EVO
Relative Strength Index (RSI) 39.97 28.43
Support Level $9.06 N/A
Resistance Level $11.27 $1.97
Average True Range (ATR) 0.54 0.05
MACD -0.06 -0.01
Stochastic Oscillator 25.00 2.70

Price Performance

Historical Comparison
OLMA
EVO

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: